You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

ENHERTU Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: ENHERTU
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for ENHERTU
Recent Clinical Trials for ENHERTU

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University of SouthamptonPhase 2
Natera, Inc.Phase 2
Guangdong Provincial People's HospitalPhase 2

See all ENHERTU clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ENHERTU Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ENHERTU Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ENHERTU Derived from Patent Text Search

No patents found based on company disclosures

ENHERTU Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for the Biologic Drug: ENHERTU

Introduction

ENHERTU (trastuzumab deruxtecan), a revolutionary antibody-drug conjugate (ADC), has been making significant waves in the oncology market, particularly in the treatment of breast cancer. Developed by Daiichi Sankyo and AstraZeneca, ENHERTU has demonstrated remarkable growth and is poised to continue its dominance in the market.

Approval and Indications

ENHERTU has received several key approvals that have driven its market success. Notably, it was approved for the treatment of HER2-positive metastatic breast cancer (mBC) in the second line in the US, based on the DESTINY-Breast03 study, which showed unparalleled improvement in progression-free survival (PFS) compared to T-DM1[1][3].

In August 2022, ENHERTU received approval for HER2-low breast cancer, previously treated with chemotherapy, marking an industry-first achievement. This approval has significantly expanded its patient base, as HER2-low breast cancer accounts for approximately 50% of breast cancer cases[1][3].

Market Performance

The market performance of ENHERTU has been nothing short of impressive. Since its launch for second-line HER2-positive breast cancer in May 2022, ENHERTU has outperformed competitors, securing the largest share of new patients in the US market. The drug's rapid uptake in the HER2-low breast cancer segment has been particularly noteworthy, achieving the number one new patient share in the US market[1][3].

Sales Growth

ENHERTU's sales have more than doubled from approximately $1.25 billion in 2022 to $2.5 billion in the subsequent year, highlighting its swift adoption and market penetration[4].

In the third quarter of FY2022, global net sales of ENHERTU reached 60.2 billion JPY, with a 25% sequential quarter-over-quarter growth. This growth was driven significantly by the US market, where the drug saw a 89.7% quarter-over-quarter growth in HR+ HER2-low mBC and a 78.9% growth in HR- HER2-low mBC[1].

Revenue Projections

The financial trajectory for ENHERTU looks promising, with the drug expected to continue its growth momentum. The antibody-drug conjugates market, in which ENHERTU is a key player, is projected to reach USD 28.61 billion by 2033. ENHERTU is among the fastest-growing segments in this market[3].

Financial Impact on Daiichi Sankyo and AstraZeneca

The success of ENHERTU has had a significant financial impact on both Daiichi Sankyo and AstraZeneca.

Daiichi Sankyo

For Daiichi Sankyo, ENHERTU has been a major driver of revenue growth. In FY2022, the company's consolidated revenue increased by 22.4% year-on-year to ¥1,278.5 billion, with ENHERTU contributing substantially to this growth. The core operating profit also increased by 35.3% year-on-year to ¥122.6 billion, partly due to the increased sales of ENHERTU[2].

AstraZeneca

AstraZeneca has also seen significant financial benefits from ENHERTU. In Q2 2024, AstraZeneca reported alliance revenue from ENHERTU at $344 million, up from $255 million in Q2 2023. This increase reflects the drug's growing market presence and adoption[5].

Market Expansion and Future Indications

ENHERTU's market expansion is not limited to its current indications. The drug is being explored for additional uses, including the potential to displace chemotherapy rather than being used after chemotherapy in the HER2-low setting. This could further broaden its patient base, potentially making it the biggest drug in breast cancer treatment[4].

Ultra-Low HER2 Setting

Studies have also demonstrated efficacy in the ultra-low HER2 setting, which could help close to 90% of women with breast cancer. This expansive potential underscores ENHERTU's transformative impact on breast cancer treatment[4].

Competitive Landscape

In the ADC market, ENHERTU competes with other notable drugs like Kadcyla. However, ENHERTU's recent approvals and its performance in new indications have positioned it as one of the fastest-growing segments in the market[3].

R&D and Investment

Both Daiichi Sankyo and AstraZeneca are investing heavily in the oncology business, including the development of ENHERTU and other ADCs. This investment is expected to drive further growth and innovation in the field[2][5].

Financial Outlook

For FY2023, Daiichi Sankyo is expecting a 13.4% increase in revenue year-on-year, driven by the continued success of ENHERTU along with other mainstay products. Core operating profit is expected to increase by 14.2% year-on-year, despite increased expenses related to the intensive investment in the oncology business[2].

Cash Flow and Investments

The financial performance of ENHERTU has also positively impacted cash flows from operating activities. In FY2022, net cash inflows from operating activities totaled ¥114.5 billion, partly due to sales-related milestones and regulatory milestones of ENHERTU[2].

Key Takeaways

  • Rapid Market Adoption: ENHERTU has seen swift adoption in both HER2-positive and HER2-low breast cancer segments.
  • Significant Revenue Growth: Sales have more than doubled from $1.25 billion in 2022 to $2.5 billion in the subsequent year.
  • Expansive Indications: The drug is being explored for additional uses, including the ultra-low HER2 setting.
  • Financial Impact: ENHERTU has driven substantial revenue and profit growth for both Daiichi Sankyo and AstraZeneca.
  • Market Dominance: ENHERTU is poised to continue its dominance in the ADC market, with projections indicating continued growth.

FAQs

What are the current approved indications for ENHERTU?

ENHERTU is approved for the treatment of HER2-positive metastatic breast cancer (mBC) in the second line and for HER2-low breast cancer previously treated with chemotherapy[1][3].

How has ENHERTU performed in terms of sales?

ENHERTU's sales have more than doubled from approximately $1.25 billion in 2022 to $2.5 billion in the subsequent year, driven by its rapid adoption in new indications[4].

What is the market potential of ENHERTU?

ENHERTU has the potential to treat close to 90% of women with breast cancer, including those with HER2-positive, HER2-low, and ultra-low HER2 settings[4].

How has ENHERTU impacted the financial performance of Daiichi Sankyo and AstraZeneca?

ENHERTU has significantly contributed to the revenue and profit growth of both companies, with substantial increases in sales and operating profits reported in recent financial results[2][5].

What are the future prospects for ENHERTU?

ENHERTU is being explored for additional indications, including the potential to displace chemotherapy, and is expected to continue its growth trajectory in the ADC market[4].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.